Australia's largest pharmaceutical company is confident it won't be affected after Donald Trump announced massive tariffs on medicines shipped to the United States.

As of Friday morning, it was unclear whether CSL would be directly impacted by the US president's proposed 100 per cent tariffs, which he announced in a post on social media.

CSL, Australia's seventh-largest public firm by market cap, makes up the bulk of Australia's $2.2 billion pharmaceutical export trade to the US.

The ASX blue-chip stock's main exports to the US are medicines derived from blood plasma manufactured at its plant in Melbourne.

But the firm also has a substantial footprint in the US, including 19,000 employees.

"CSL will be actively monitoring further announcements from the administration in relation to th

See Full Page